

MAMMAPRINT® RISK GROUP

UltraLow Risk




Your care team has ordered the MammaPrint® and Blueprint® tests for your tumor. These tests help to better understand the biology of your tumor, providing important information to create the most personalized and informed treatment recommendation for you.



MAMMAPRINT+BLUEPRINT

Illuminating Tumor Biology

UltraLow Risk



Treatment Options

CHEMOTHERAPY

Studies have shown that tumors that fall in the UltraLow Risk group have a very low chance of recurring within the first eight years. They also show that chemotherapy is unlikely to help.¹ Talk to your healthcare provider—avoiding chemotherapy may spare you from unnecessary treatment and side effects.

HORMONAL THERAPY

For most hormone-positive tumors, the standard treatment includes taking hormone therapy for five years.² However, if you are post-menopausal, have no cancer in your lymph nodes, and your MammaPrint result shows an UltraLow risk, studies suggest you may not need the full five years of therapy.³ If you are experiencing significant side effects, talk to your healthcare provider—shortening the duration of hormonal therapy may be a safe option.

MammaPrint and Blueprint are two tests that work together to provide your care team with valuable insights into your tumor. These tests should be considered alongside other clinical and pathological information in partnership with your medical team. Please consult your test results for more detailed information and your care team when making decisions about your treatment.

Scan here to
continue learning
about MammaPrint
and Blueprint



MKT-203-V1

1. Lopes Cardozo AM, et al. Journal of Clinical Oncology. 2022
2. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 3.2024.
3. Esserman LJ, et al. JAMA Oncol. November 2017.

